Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
March 10th, 2023
6.5K views
Novel strategies to faithfully model somatic mutations in hematopoietic stem and progenitor cells (HSPCs) are necessary to better study hematopoietic stem cell biology and hematological malignancies. Here, a protocol to model heterozygous gain-of-function mutations in HSPCs by combining the use of CRISPR/Cas9 and dual rAAV donor transduction is described.
Overview
This article presents a protocol for modeling heterozygous gain-of-function mutations in hematopoietic stem and progenitor cells (HSPCs) using CRISPR/Cas9 and dual rAAV donor transduction. This method enables the precise study of leukemogenic mutations and their role in leukemic transformation.
Key Study Components
Area of Science
- Hematopoietic stem cell biology
- Hematological malignancies
- Gene editing techniques
Background
- Understanding somatic mutations in HSPCs is crucial for studying blood cancers.
- Current methods lack precision in modeling these mutations.
- CRISPR/Cas9 technology offers a powerful tool for genetic engineering.
- Fluorescent reporters facilitate tracking of modified cells.
Purpose of Study
- To develop a reliable method for modeling specific mutations in HSPCs.
- To investigate the impact of these mutations on leukemic transformation.
- To enhance the understanding of hematopoietic malignancies.
Methods Used
- Designing single guide RNA using Benchling.
- Creating HDR templates for gene editing.
- Transducing HSPCs with recombinant AAVs.
- Electroporating cells to introduce CRISPR components.
Main Results
- Successful modeling of gain-of-function mutations in HSPCs.
- Identification and enrichment of heterozygously-mutated cell populations.
- Demonstrated the potential for studying leukemic transformation.
- Established a protocol that can be replicated in other labs.
Conclusions
- The combined use of CRISPR/Cas9 and rAAV is effective for gene editing in HSPCs.
- This method provides insights into the mechanisms of hematological malignancies.
- Future studies can leverage this protocol to explore other mutations.
Frequently Asked Questions
What are hematopoietic stem and progenitor cells?
Hematopoietic stem and progenitor cells are the cells responsible for the formation of blood cells in the body.
How does CRISPR/Cas9 work?
CRISPR/Cas9 is a gene-editing technology that allows for precise modifications of DNA sequences in living organisms.
What is the significance of using fluorescent reporters?
Fluorescent reporters enable researchers to track and analyze specific cell populations that have undergone genetic modifications.
Can this method be applied to other types of cells?
Yes, the principles of this method can be adapted for use in various cell types beyond HSPCs.
What are the potential applications of this research?
This research can help in understanding blood cancers and developing targeted therapies.
Who conducted the study?
The study was conducted by Tommaso Sconocchia, a post-doctoral research fellow.
Executive Industry Relevance
Modeling heterozygous gain-of-function mutations in human hematopoietic stem and progenitor cells (HSPCs) addresses a critical gap in understanding leukemogenic mechanisms and target validation for hematologic malignancies. This dual-reporter CRISPR/AAV6 workflow enables precise interrogation of oncogenic mutations, supporting predictive confidence at the discovery and preclinical inflection points. The approach enhances portfolio decision-making by enabling functional de-risking of candidate targets implicated in blood cancers.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional modeling of recurrent oncogenic mutations in primary human HSPCs.
- Supports mechanistic de-risking by isolating the effects of heterozygous gain-of-function alleles.
- Facilitates target validation through direct assessment of mutation-driven phenotypes.
- Improves predictive confidence for prioritizing targets in hematologic malignancy pipelines.
Screening & Assay Development
- Provides validated, genetically defined HSPC populations for downstream functional assays.
- Dual fluorescent reporters allow for robust tracking and enrichment of edited cell populations.
- Enables reproducible generation of disease-relevant cell models for compound screening.
- Standardizes assay inputs by ensuring precise genetic backgrounds in test systems.
Translational & Preclinical Research
- Aligns engineered HSPC models with disease-relevant mechanisms for translational studies.
- Supports continuity from in vitro functional assays to in vivo transplantation models.
- Facilitates risk-adjusted advancement of targets based on mechanistic and phenotypic data.
- Enables exploration of mutation-driven progression toward hematological malignancies.
Pipeline & Workflow Integration
This method integrates at the interface of early discovery, target validation, and preclinical model development for hematologic malignancy research.
- Discovery Biology: Enables hypothesis testing of oncogenic mutations and clarifies their mechanistic impact in primary HSPCs.
- Screening: Provides genetically defined, reproducible cell populations for quantitative functional assays.
- Analytics: Dual reporter system and downstream sequencing enable precise measurement and comparison of edited versus wild-type cells.
- Translational Research: Supports preclinical continuity by enabling in vitro and in vivo functional studies of engineered HSPCs.
- Enterprise Reuse: Establishes a reusable platform for modeling diverse mutations across hematopoietic targets.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes genetic engineering and cell sorting workflows for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in hematologic portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on functional and mechanistic data.
Implementation Considerations
- Requires expertise in CRISPR/Cas9 design, AAV6 vector production, and HSPC culture.
- Demands access to flow cytometry and molecular cloning infrastructure for reporter-based sorting and validation.
- Necessitates rigorous guide RNA selection to maximize HDR efficiency and editing fidelity.
- Adaptation to other gene targets or cell types may require optimization of homology arms and reporter constructs.
- Efficiency and scalability are influenced by cell viability, transduction conditions, and sorting accuracy.
Biopharma FAQs
Why does null hypothesis testing matter for dual-reporter HSPC editing?
Null hypothesis testing enables rigorous evaluation of whether engineered heterozygous gain-of-function mutations in HSPCs produce statistically significant phenotypic changes compared to controls. This is essential for target validation and for distinguishing true biological effects from background variability. Such statistical rigor supports confident advancement of candidate targets in hematologic malignancy pipelines.
How does independent variable isolation fit the CRISPR/AAV6 workflow?
The dual fluorescent reporter system allows precise isolation of HSPC populations with specific genetic edits, ensuring that observed functional outcomes are attributable to the engineered mutation. This isolation is critical for mechanistic de-risking and for generating reproducible, interpretable data in early discovery and preclinical studies.
What do quantitative dependent variable measurements enable in functional HSPC assays?
Quantitative measurements, such as flow cytometry-based reporter expression and downstream sequencing, enable objective assessment of editing efficiency and functional impact. These outputs support robust comparison between wild-type and mutant HSPCs, informing target prioritization and mechanistic understanding.
Why are replication requirements important for cross-functional HSPC studies?
Replication ensures that observed effects of heterozygous gain-of-function mutations are consistent and reproducible across experiments and teams. This is vital for cross-functional collaboration, assay transferability, and for building confidence in data used for portfolio decisions.
What statistical analysis capabilities are required before implementing dual-reporter HSPC editing?
Implementation requires statistical tools for analyzing editing efficiency, population enrichment, and functional assay outputs. Capabilities must include comparison of engineered versus control populations and validation of significant phenotypic changes, supporting data-driven advancement in discovery and preclinical workflows.
Chapters in this video
0:05
Introduction
0:54
sgRNA Design
1:57
Homology-Directed Repair Vector Construction
5:42
Editing of Hematopoietic Stem and Progenitor Cells
9:48
Results: Heterozygous Gain-of-Function Mutations in Hematopoietic Stem and Progenitor Cells by Combining the Use of CRISPR/Cas9 and Dual rAAV Donor Transduction
11:19
Conclusion
